An observational study in Acute Coronary Syndrome, sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases · Observational
To develop and implement quality improvement programs for the treatment of acute coronary syndrome (ACS) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of acute coronary syndrome.
1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.
This study's enrollment of 124,363 is above the median of 500 across 561 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Beijing Institute of Heart, Lung and Blood Vessel Diseases is the lead sponsor of 23 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospitalized patients with acute coronary syndrome
Hospitalized patients with discharge diagnosis as acute coronary syndrome (including STEMI, NSTEMI and UAP) in 150 tertiary and 100 secondary hospitals.
Exclusion Criteria:
None
The overall composite of 11 performance measures for ACS care
Performance measures for ACS care including: 1. Proportion of patients received aspirin at arrival 2. Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) 3. Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) 4. Proportion of patients received reperfusion therapy (STEMI) 5. Proportion of patients with aspirin prescribed at discharge 6. Proportion of patients with clopidogrel or other P2Y12 inhibitors prescribed at discharge 7. Proportion of patients with beta-blocker prescribed at discharge 8. Proportion of patients with statin prescribed at discharge 9. Proportion of patients received evaluation of left ventricular systolic function 10. Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge 11. Proportion of patients received smoking cessation advice/ counseling
Time frame: Duration of hospital stay, an expected average of 1 week
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Institute of Heart, Lung and Blood Vessel Diseases